Logo

Pfizer and BioNTech Seek the US FDA’s EUA for Booster Dose in Older Patients

Share this
Pfizer and BioNTech Seek the US FDA’s EUA for Booster Dose in Older Patients

Pfizer and BioNTech Seek the US FDA’s EUA for Booster Dose in Older Patients

Shots:

  • The companies have submitted an application to the US FDA for EUA of an additional booster dose for adults ≥65yrs. who have received an initial booster of any approved COVID-19 vaccines
  • The submission was based on two real-world safety and efficacy data from Israel that showed 2 times reduction in rates of confirmed infections and 4 times reduction in rates of severe illness in patients who received additional booster dose of Comirnaty vs who have received the only initial booster
  • The submission also includes results from ongoing in healthcare workers aged≥18yrs. in Israel who had been vaccinated with three doses of Comirnaty that showed no new safety concern were observed 

Ref: Pfizer | Image: Pfizer

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions